Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

NEXT STORY
Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting
PREV STORY
BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

SANTA CLARA, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary ...

author_avatar
NASDAQ Market News

Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings

OXFORD, United Kingdom, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), ...

author_avatar
NASDAQ Market News

Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305

G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support ...

author_avatar
NASDAQ Market News